Edwards Lifesciences
EW
Delayed Nyse - 02/21 10:01:23 pm
134.25USD
-0.05%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 20172018
Sales3 4353 842
EBITDA-1 259
Operating profit (EBIT)1 0221 169
Pre-Tax Profit (EBT)--
Net income622936
EPS ( $ )2,884,38
Dividend per Share ( $ )--
Yield--
Announcement Date02/01/2018
09:41pm
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 20172018
Debt--
Finance301639
Operating income (EBITDA)-1 259
Leverage
(Debt/EBITDA)
--
Capital Expenditure168170
Book Value Per Share (BVPS)14,2 $14,3 $
Cash Flow per Share4,63 $4,00 $
Announcement Date02/01/2018
09:41pm
-
Balance Sheet Analysis
Financial Ratios
Size 2018e 2019e
Capitalization 28 410 M$ -
Entreprise Value (EV) 27 771 M$ 27 216 M$
Valuation 2018e 2019e
P/E ratio (Price / EPS) 30,7x 27,2x
Capitalization / Revenue 7,39x 6,74x
EV / Revenue 7,23x 6,46x
EV / EBITDA 22,0x 19,5x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 9,38x 7,83x
Profitability 2018e 2019e
Operating Margin (EBIT / Sales) 30,4% 31,1%
operating Leverage (Delta EBIT / Delta Sales) 1,22x 1,25x
Net Margin (Net Profit / Revenue) 24,4% 24,8%
ROA (Net Profit / Asset) 16,1% 16,8%
ROE (Net Profit / Equities) 27,0% 27,1%
Rate of Dividend - -
Balance Sheet Analysis 2018e 2019e
CAPEX / CA   4,43% 4,73%
Cash Flow / Sales 21,8% 25,5%
Capital Intensity (Assets / Sales) 1,51x 1,48x
Financial Leverage (Net Debt / EBITDA) -0,51x -0,85x
Price Earning Ratio
BNA & Dividende